| Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment N Giuliani, R Bataille, C Mancini, M Lazzaretti, S Barillé Blood, The Journal of the American Society of Hematology 98 (13), 3527-3533, 2001 | 564 | 2001 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 546 | 2020 |
| Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation N Giuliani, S Colla, F Morandi, M Lazzaretti, R Sala, S Bonomini, M Grano, ... Blood 106 (7), 2472-2483, 2005 | 400 | 2005 |
| Multiple myeloma bone disease: pathophysiology of osteoblast inhibition N Giuliani, V Rizzoli, GD Roodman Blood 108 (13), 3992-3996, 2006 | 388 | 2006 |
| Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA–Italian Multiple Myeloma Network A Palumbo, P Falco, P Corradini, A Falcone, F Di Raimondo, N Giuliani, ... J Clin Oncol 25 (28), 4459-4465, 2007 | 380 | 2007 |
| Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in … N Giuliani, M Pedrazzoni, G Negri, G Passeri, M Impicciatore, G Girasole Bone 22 (5), 455-461, 1998 | 352 | 1998 |
| Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease N Giuliani, S Colla, R Sala, M Moroni, M Lazzaretti, S La Monica, ... Blood, The Journal of the American Society of Hematology 100 (13), 4615-4621, 2002 | 335 | 2002 |
| Increased Risk for Venous Thrombosis in Carriers of the Prothrombin G→A20210 Gene Variant M Margaglione, V Brancaccio, N Giuliani, G D'Andrea, G Cappucci, ... Annals of internal medicine 129 (2), 89-93, 1998 | 325 | 1998 |
| The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients N Giuliani, F Morandi, S Tagliaferri, M Lazzaretti, S Bonomini, M Crugnola, ... Blood, The Journal of the American Society of Hematology 110 (1), 334-338, 2007 | 304 | 2007 |
| The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition G Bianchi, L Oliva, P Cascio, N Pengo, F Fontana, F Cerruti, A Orsi, ... Blood, The Journal of the American Society of Hematology 113 (13), 3040-3049, 2009 | 272 | 2009 |
| IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma LA Ehrlich, HY Chung, I Ghobrial, SJ Choi, F Morandi, S Colla, V Rizzoli, ... Blood 106 (4), 1407-1414, 2005 | 240 | 2005 |
| Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program DL Pagano, C Girmenia, L Mele, P Ricci, ME Tosti, A Nosari, M Buelli, ... haematologica 86 (8), 862-870, 2001 | 211 | 2001 |
| Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients A Palumbo, F Gay, P Falco, C Crippa, V Montefusco, F Patriarca, ... J Clin Oncol 28 (5), 800-807, 2010 | 194 | 2010 |
| Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking M Salvi, M Pedrazzoni, G Girasole, N Giuliani, R Minelli, JR Wall, E Roti European Journal of Endocrinology 143 (2), 197-202, 2000 | 194 | 2000 |
| Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease M Salvi, G Girasole, M Pedrazzoni, M Passeri, N Giuliani, R Minelli, ... The Journal of Clinical Endocrinology & Metabolism 81 (8), 2976-2979, 1996 | 189 | 1996 |
| Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age-and menopause-related changes N Giuliani, P Sansoni, G Girasole, R Vescovini, G Passeri, M Passeri, ... Experimental gerontology 36 (3), 547-557, 2001 | 178 | 2001 |
| Bisphosphonates inhibit IL-6 production by human osteoblast-like cells N Giuliani, M Pedrazzoni, G Passeri, G Girasole Scandinavian journal of rheumatology 27 (1), 38-41, 1998 | 178 | 1998 |
| CD38: a target for immunotherapeutic approaches in multiple myeloma F Morandi, AL Horenstein, F Costa, N Giuliani, V Pistoia, F Malavasi Frontiers in immunology 9, 408458, 2018 | 170 | 2018 |
| The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible … S Colla, S Tagliaferri, F Morandi, P Lunghi, G Donofrio, D Martorana, ... Blood, The Journal of the American Society of Hematology 110 (13), 4464-4475, 2007 | 169 | 2007 |
| Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone … F Gay, P Musto, D Rota-Scalabrini, L Bertamini, A Belotti, M Galli, ... The Lancet Oncology 22 (12), 1705-1720, 2021 | 166 | 2021 |
